abstract |
The invention relates to a solid oral pharmaceutical composition comprising an S1P receptor agonist selected from 2-amino-2- [4- (3-benzyloxyphenoxy) -2-chlorophenyl] propyl-1,3-propanediol, 2 -Amino-2- [4- (benzyloxyphenylthio) -2-chlorophenyl] propyl-1,3-propanediol or pharmacologically acceptable salts thereof, wherein the composition comprises the S1P receptor agonist in combination with a sugar alcohol. |